Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-141 · 1 trial · 1 indication
Cmax of ABBV-141 will be assessed.
Tmax of ABBV-141 will be assessed.
AUCt of ABBV-141 will be determined.
AUCinf of ABBV-141 will be assessed.
Terminal phase elimination rate constant (β) of ABBV-141 will be assessed.
Terminal phase elimination half-life (t1/2) of ABBV-141 will be assessed.
Dose normalized Cmax of ABBV-141 will be assessed.
Dose normalized AUC of ABBV-141 will be assessed.
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| Arm | Type | Description |
|---|---|---|
| Part 1, ABBV-141 (Intravenous [IV]) | EXPERIMENTAL | Western participants will receive a single IV dose of ABBV-141. |
| Part 1, Placebo for ABBV-141 (IV) | PLACEBO_COMPARATOR | Western participants will receive a single IV dose of placebo for ABBV-141. |
| Part 1, ABBV-141 (subcutaneous [SC]) | EXPERIMENTAL | Western participants will receive a single SC dose of ABBV-141. |
| Part 1, Placebo for ABBV-141 (SC) | PLACEBO_COMPARATOR | Western participants will receive a single SC dose of placebo for ABBV-141. |
| Part 2, ABBV-141 (IV) | EXPERIMENTAL | Asian participants will receive a single IV dose of ABBV-141. |
| Part 2, Placebo for ABBV-141 (IV) | PLACEBO_COMPARATOR | Asian participants will receive a single IV dose of placebo for ABBV-141. |
| Part 2, ABBV-141 (SC) | EXPERIMENTAL | Asian participants will receive a single SC dose of ABBV-141. |
| Part 2, Placebo for ABBV-141 (SC) | PLACEBO_COMPARATOR | Asian participants will receive a single SC dose of placebo for ABBV-141. |
| Name | Type | Description |
|---|---|---|
| ABBV-141 | DRUG | Infusion; intravenous (IV) |
| Placebo for ABBV-141 | DRUG | Infusion; IV |
Inclusion Criteria: * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG). * Body Mass Index (BMI) is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal. For Part 2 onl...
ABBV-141 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating how single ascending doses of the drug move through the body of healthy adult Western and Asian participants.
ABBV-141 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting early-stage clinical research on this investigational small molecule.
ABBV-141 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and how it is processed by the body.
ABBV-141 has one completed Phase 1 clinical trial, registered as NCT06148181. The study evaluated adverse events and how single ascending doses of ABBV-141 move through the body of healthy adult Western and Asian participants in the United States.
Yes, ABBV-141 is a small molecule drug. It is being investigated in a Phase 1 clinical trial involving healthy volunteers, with the study designed as a randomized, double-blind, placebo-controlled trial.